Botanical species · safety record

Erythroxylum laurifolium

The EFSA Compendium of Botanicals holds 4 constituent measurements and 3 adverse-effect records for Erythroxylum laurifolium. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Erythroxylum laurifolium Lam.

4Constituent measurements

3Safety records

2Cited sources

0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Tannins	Leaves	Drying (dehydration)	≥ 10 Percent	—	No resolvable identifier
Tannins	Bark	Drying (dehydration)	≤ 13.6 Percent	—	No resolvable identifier
Tannins	Leaves	Drying (dehydration)	≤ 15 Percent	—	No resolvable identifier
Tannins	Bark	Drying (dehydration)	≥ 13 Percent	—	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Digestive	Digestive	Unspecified	Solvent extraction	—	In vitro	Resolve DOI
Digestive	Digestive	Unspecified	Solvent extraction	—	In vitro	Resolve DOI
Digestive	Digestive: pancreas	Unspecified	Solvent extraction	—	In vitro	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Picot, Carene M N., Subratty, A Hussein., Mahomoodally, M Fawzi. Inhibitory Potential of Five Traditionally Used Native Antidiabetic Medicinal Plants on alpha -Amylase, alpha -Glucosidase, Glucose Entrapment, and Amylolysis Kinetics In Vitro.. Advances in pharmacological sciences, 2014, vol. 2014, p. 739834-739834. DOI
Bezanger-Beauquesne, L., Guilbert, N., Deneck, D. Investigation of Erythroxylum laurifolium. Annales Pharmaceutiques Francaises, 1965, p. 377-384.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature